Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Stomach Neoplasms 1Sarcoma, Myeloid 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × devimistat × Clear all
NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT01830322 2013-08-14

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Cornerstone Pharmaceuticals

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡